Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise only

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: HDM1002 200 mg — HDM1002 tablets, 200 mg once daily
  • Drug: HDM1002 400 mg — HDM1002 tablets, 400 mg once daily
  • Drug: Placebo — Placebo tablets, once daily

Primary Outcomes

  • Change From Baseline in HbA1c at Week 40 (Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-08-12
Completion: 2027-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Linong Ji
010-88325578
jiln@bjmu.edu.cn
Peking University People's Hospital
Interventions
  • Drug: HDM1002 200 mg — HDM1002 tablets, 200 mg once daily
  • Drug: HDM1002 400 mg — HDM1002 tablets, 400 mg once daily
  • Drug: Placebo — Placebo tablets, once daily
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100000 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female subjects between 18 and 75 years of age (inclusive). 2. Have been diagnosed with type 2 diabetes mellitus (T2DM) for at least 10 weeks based on the World Health Organization, and meet the following conditions:a) had been treated with diet and exercise for at least 10 weeks prior to signing ICF; b) Not been treated with any hypoglycemic drugs within 10 weeks prior to signing ICF. 3. HbA1c ≥7.5% and ≤10.5% at screening as assessed by the local laboratory, and HbA1c ≥7.5% and ≤10.5% prior to randomization as assessed by the specified central laboratory. 4. Having a body mass index (BMI) of 22.5 to 40.0 kg/m2, inclusive. 5. Female participants of childbearing potential and male participants must agree to use highly effective contraception method from the day of signing the ICF and until 30 days (female) or 90 days (male) after the final dose administration. 6. Able to understand and comply with protocol requirements, agree to maintain the same dietary and exercise habits throughout the trial, be willing to complete the trial in strict compliance with the clinical trial protocol and provide written informed consent. Exclusion Criteria: 1. Diagnosed with type 1 diabetes mellitus (including latent autoimmune diabetes in adults), special types of diabetes or gestational diabetes mellitus 2. Evidence of acute complications of diabetes (e.g., diabetic ketoacidosis, diabetic lactosidosis, or hyperosmolar nonketotic coma) within 6 months prior to signing ICF. 3. Have a known self or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia or multiple endocrine neoplasia type II (MEN2) 4. History of acute or chronic pancreatitis or pancreatic injury, or any high-risk factor which may lead to pancreatitis; or have symptomatic gallbladder disease that requires treatment during the trial (subjects with prior cholecystectomy can be enrolled if deemed eligible by the investigator) 5. Have had dysphagia, or any condition or disease possibly affecting gastric emptying or nutrients absorption in the opinion of the investigator, such as history of surgery affecting gastric emptying, gastroesophageal reflux disease, pyloric obstruction, irritable bowel syndrome, etc. 6. Have had any of the following within 3 months prior to screening: * Unstable angina; * Heart failure (New York Heart Association, class III or IV); * Myocardial infarction (MI); * Coronary artery bypass grafting or percutaneous coronary intervention; * Uncontrolled severe arrhythmias (including: ventricular tachycardia, ventricular fibrillation, atrial fibrillation, second to third degree atrioventricular block, sick sinus node syndrome, pre-excitation syndrome, etc.); * Cerebrovascular accident 7. Have a history of proliferative diabetic retinopathy and/or diabetic maculopathy that requires treatment, or evidence of other severe retinopathy that requires treatment during the study. 8. Have a known history of liver disease, including: acute or chronic active liver disease (except non-alcoholic steatohepatitis) such as active hepatitis B, hepatitis C; or primary biliary cholangitis. 9. Those who have used the following drugs within 14 days before randomization or within 5 half-lives (whichever is longer), or who need to use the following drugs for a long time during the trial, are excluded: strong or moderate inhibitors of cytochrome P450 enzyme (CYP) 3A4, strong inducers of CYP3A4, strong inhibitors of P-gp, strong inducers of P-gp, inhibitors of OATP1B1 or OATP1B3, or narrow therapeutic index drugs that are CYP2C8, CYP3A4, UGT1A1, P-gp, OATP1B1 or OATP1B3 substrates. 10. Use of any glucose-lowering medication within 10 weeks prior to signing ICF, including but not limited to: α-glucosidase inhibitors (e.g., acarbose), thiazolidinediones, and dipeptidyl peptidase-4 inhibitors (DPP-4i) inhibitors, glucose kinase activators, sodium-glucose cotransporter-2 inhibitors (SGLT-2i) ,with the exception of short-term insulin therapy due to a concomitant illness, stress, or perioperative period (cumulative duration ≤ 14 days). 11. Having used a Glucagon-like peptide-1 (GLP-1) analogue within 3 months prior to signing the ICF; or previous discontinuation of a GLP-1 analogue due to safety/tolerability or lack of efficacy. 12. Pregnancy or lactation. 13. Subjects with a known hypersensitivity to GLP-1 receptor agonists (GLP-1RA), or a history of severe drug allergies. 14. Enrolled in or participated in any other clinical study of drugs or medical devices within 3 months (or within 5 half-lives, whichever is longer) prior to signing the ICF (except for subjects who signed written informed consent without any intervention of investigational product or medical devices). 15. Any other condition considered by the investigator which is not suitable for participating in this study.
Conditions Prevention
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Alpha Lipoic Acid — alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA.

Primary Outcomes

  • Incidence of development of radiation induced dermatitis (RID) (weekly after every fifth Radiotherapy session till the end of study (3 weeks).)
  • Evaluation of the Severity of radiation-induced dermatitis (RID) developed (weekly after every fifth Radiotherapy session till the end of study (3 weeks).)
  • Evaluation of Inflammatory biomarker level (Interleukin-6) (baseline, end of study Up to 3 Weeks)
  • Evaluation of Incidence of Treatment-Emergent Adverse Events (weekly after every fifth Radiotherapy session till the end of study (3 weeks).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-06
Completion: 2025-12-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Principal Investigators:
  • Rana Mohamed Elsayed Kelany Abdelkader (PRINCIPAL_INVESTIGATOR) - Faculty of Pharmacy, Ain Shams University
Contact Information
Study Contact:
Rana Mohamed Elsayed Kelany Abdelkader
00201023262639
rana.mohamed18@pharma.asu.edu.eg
Rana Mohamed Elsayed Kelany Abdelkader
00201023262639
rana.mohamed18@pharma.asu.edu.eg
Zagazig University Hospitals
Interventions
  • Dietary Supplement: Alpha Lipoic Acid — alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA.
Study Locations (1 sites)
Zagazig University Hospitals, Zagazig, Egypt
Eligibility Criteria
Inclusion Criteria: * Women aged ≥18 years. * Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy. * Receiving total radiation dose of 40 Gy for 15 sessions. Exclusion Criteria: * Prior exposure to radiotherapy. * Inflammatory or metastatic breast carcinoma. * Patients with connective tissue disorders. * Patients with skin inflammatory diseases (e.g. ectopic dermatitis). * Patients with known allergy or hypersensitivity to alpha lipoic acid. * Concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or antioxidant medications. * Patients who will fail to sign the written consent.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer in women in the United Kingdom (UK). Most women are treated with a combination of surgery and radiotherapy. While these treatments are effective, they can cause ongoing breast pain for some, which can last months or even years. This long-term pain can have a major impact on quality of life, yet it is often overlooked and not well managed in routine care. One in three women may still experience breast pain three years after treatment. The pain can come from scarring, tissue damage, or nerve changes caused by surgery and radiotherapy. Treatments for this pain are limited. Many patients are advised the pain will subside on its own or are given basic painkillers, which sometimes have limited impact. ScarWork is a light-touch manual therapy, developed in the United States and aims to improve the way scars feel and look, reduce pain and tightness, and support healing. Although it has been available in the United Kingdom since 2014, there is very little research into whether ScarWork helps people who experience pain after breast cancer treatment. This small study is a first step to see whether ScarWork could be a useful treatment for people who have experience breast pain after surgery and/or radiotherapy. The researchers want to know: * Can this therapy be delivered in an NHS setting? * Do people find it helpful? * Is it worth doing a larger trial in the future? Participants will be randomly placed in one of two groups: one group will continue with usual care, and the other will receive up to five sessions of ScarWork in addition to usual care. Everyone in the study will be asked to complete short questionnaires about their pain and other symptoms, before and after treatment, and again one month later. Participants will also be invited to talk about their experiences in a short phone or online interview. This research will help show whether ScarWork might be a useful option for people dealing with breast pain after treatment. It will also help researchers design a larger trial in the future to test ScarWork more fully.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: ScarWork therapy — ScarWork is a manual therapy technique involving gentle, hands-on massage of scar tissue. It is designed to improve the mobility and integration of scar tissue, reduce discomfort, and support tissue healing. The approach is tailored to each individual, based on the characteristics of their scar and sensitivity of the surrounding tissue. It is commonly used with people recovering from surgery or radiotherapy to help address symptoms such as pain, tightness, numbness, or altered sensation. In this study, participants in the intervention group will receive up to five ScarWork sessions delivered by a trained therapist, in addition to standard care.

Primary Outcomes

  • BREAST-Q Breast Conserving Therapy Module V2.0 (Baseline (Week 0, before first session), Week 12 (at final ScarWork session; control group same time point), Week 16 (4 weeks post-final session; control group same time point).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-20
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College London Hospitals
Collaborators: University of West London
Contact Information
Study Contact:
Nicole Collaco
+4489 484 435 22
nicole.collaco@nhs.net
Royal London Hospital for Integrated Medicine
John Hughes
john.hughes8@nhs.net
Royal London Hospital for Integrated Medicine
Nicole Collaco
Royal London Hospital for Integrated Medicine
Interventions
  • Other: ScarWork therapy — ScarWork is a manual therapy technique involving gentle, hands-on massage of scar tissue. It is designed to improve the mobility and integration of scar tissue, reduce discomfort, and support tissue healing. The approach is tailored to each individual, based on the characteristics of their scar and sensitivity of the surrounding tissue. It is commonly used with people recovering from surgery or radiotherapy to help address symptoms such as pain, tightness, numbness, or altered sensation. In this study, participants in the intervention group will receive up to five ScarWork sessions delivered by a trained therapist, in addition to standard care.
Study Locations (1 sites)
Royal London Hospital for Integrated Medicine, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Over the age of 18 * Early breast cancer patients who have had breast surgery with curative intent * Radiotherapy completed ≥ 6 months previously * In remission with no sign of active local disease * Registering a score of ≥3 on perceived pain intensity or pain burden on a 10-point numerical rating scale (NRS) * English speaking and able to communicate reasonably well * Able to give informed consent * Willing to attend for regular treatment at RLHIM Exclusion Criteria: * History of post-breast surgery wound complications * History of breast surgery unrelated to breast cancer treatment * History of previous ScarWork therapy * Diagnosis of lymphoedema * Severe co-morbidities or cognitive disability * Receiving physiotherapy for post-breast surgery pain syndrome at the time of trial
Conditions Melanoma (Skin Cancer), HER2-low Hormone...
Phase PHASE1, PHASE2
Enrollment 92
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and capivasertib * Cohort 2: Patients with unresectable or metastatic cutaneous melanoma receiving pembrolizumab The Phase 1b portion will find the recommended Phase 2 dose (RP2D). The Phase 2 portion will further evaluate clinical activity at the RP2D using response criteria for solid tumors (RECIST 1.1). The study will also evaluate pharmacokinetics, pharmacodynamics, disease control, and overall safety.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AMXT 1501 Dicaprate — Formulation: Enteric-coated oral tablet (100 mg base) Dose: Body-surface-area-adjusted; starting dose = 300 mg PO BID; may escalate per 3 + 3 design Administration: By mouth on an empty stomach (AM and PM doses)
  • Drug: DFMO — Formulation: 500 mg gel capsule Dose: 500 mg PO once or twice daily, per cohort dose level
  • Drug: Fulvestrant — Dose: 500 mg IM injection on Day 2 and Day 15 of Cycle 1, then Day 2 of each subsequent 28-day cycle
  • Drug: Capivasertib — Dose: 400 mg PO BID for 4 days on / 3 days off each week (28-day cycle)
  • Drug: Pembrolizumab — 200 mg IV infusion every 3 weeks (Q3W) for up to 12 months

Primary Outcomes

  • Incidence of Dose-Limiting Toxicities (DLTs) (Within 24 months of last patient enrolled)
  • Incidence, Frequency, and Severity of Adverse Events (AEs) (Within 24 months of last patient enrolled)
  • Objective Response Rate (ORR) (Phase 2) (Within 24 months of last patient enrolled)
  • Duration of Response (DOR) (Phase 2) (Within 24 months of last patient enrolled)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-26
Completion: 2028-12-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 92 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aminex Therapeutics, Inc.
Principal Investigators:
  • Deyaa Adib, MD (STUDY_DIRECTOR) - Aminex Therapeutics, Inc.
Contact Information
Study Contact:
Mark Burns, PhD
425-524-1615
mburns@aminextx.com
Spencer Williams
520-694-4374
spencerwilliams@arizona.edu
University of Arizona
Jeanette Cadenas
serranoj@arizona.edu
University of Arizona
Interventions
  • Drug: AMXT 1501 Dicaprate — Formulation: Enteric-coated oral tablet (100 mg base) Dose: Body-surface-area-adjusted; starting dose = 300 mg PO BID; may escalate per 3 + 3 design Administration: By mouth on an empty stomach (AM and PM doses)
  • Drug: DFMO — Formulation: 500 mg gel capsule Dose: 500 mg PO once or twice daily, per cohort dose level
  • Drug: Fulvestrant — Dose: 500 mg IM injection on Day 2 and Day 15 of Cycle 1, then Day 2 of each subsequent 28-day cycle
  • Drug: Capivasertib — Dose: 400 mg PO BID for 4 days on / 3 days off each week (28-day cycle)
  • Drug: Pembrolizumab — 200 mg IV infusion every 3 weeks (Q3W) for up to 12 months
Study Locations (20 sites)
University of Arizona, Tucson, Arizona 85724 United States
University of California-San Diego, La Jolla, California 92037 United States
START Los Angeles, Los Angeles, California 90025 United States
University of California-San Fransisco, San Francisco, California 94158 United States
Skin Cancer Institute, Englewood, Colorado 80113 United States
University of Kansas Hospital-Cancer Center, Fairway, Kansas 66205 United States
Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove, Minnesota 55369 United States
START Cancer Research New York-Long Island, Lake Success, New York 11042 United States
University of Cincinnati Medical Center, Cincinnati, Ohio 45219 United States
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for study participation only if they meet ALL the inclusion criteria applicable to their diagnosis. 1. Understand and sign the informed consent form (ICF) and be willing to comply with all study procedures before any study specific procedures are conducted. 2. ≥18 years old at the time of signing the informed consent. 3. Diagnosed with unresectable, locally advanced, or metastatic solid tumors including ER+ HER2- breast cancer (Cohort 1) or melanoma (Cohort 2) a.Underlying malignant disease must be histologically or cytologically documented b.For breast cancer patients: locally advanced or metastatic breast cancer with one or more actionable PIK3CA/AKT1/PTEN-alterations following progression on at least 2 endocrine-based regimens in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Patients who are candidates to start therapy with capivasertib are eligible for enrollment. Patients previously treated with PIK3CA inhibitors will be allowed into the study. Premenopausal patients with ER+ HER2-breast cancer may be enrolled and should be maintained on an agent for ovarian suppression (i.e., luteinizing hormone-releasing hormone \[LHRH\] agonist) as part of SOC. c.For melanoma patients: patients with unresectable metastatic cutaneous melanoma that progressed on any prior immune checkpoint inhibitor and, if BRAF600 mutant positive, a BRAF or mitogen-activated protein kinase (MEK) inhibitor or both as shown below: i.Patient have to have resolution of all immune checkpoint inhibitor-related adverse events to Grade 0-1 and prednisone ≤10 mg/day for at least 2 weeks. Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy. ii.Patients must have progressed or shown intolerance to any prior immune checkpoint inhibitors. iii.Patients with BRAF gene mutant melanoma must have had a prior treatment regimen (progressed or shown intolerance) that included vemurafenib, dabrafenib, or an approved BRAF gene and or MEK protein inhibitor. However, patients who may continue to be candidates for second line immune check point inhibitors can be enrolled prior to initiation for BRAF gene or MEK inhibitors. iv.Patients with incurable malignancies may be enrolled regardless of the number of prior treatment lines, as long as in the opinion of the Investigator, the patient would be unlikely to tolerate or derive clinically meaningful benefit from other available treatment options (FDA Guidance for Industry: Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings. July 2022). d.Has evaluable or measurable disease by tumor Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) at the time of enrollment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. e.Patients with brain previously treated stable brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. 4. Patients must be willing to undergo a fresh tumor biopsy at Screening and during treatment if safe and clinically feasible. An archival sample is allowed if obtained within 1 year prior to the first dose of study drug. However, lack of tumor biopsy by itself will not preclude patients from enrollment. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening or Day 1. 6. Life expectancy of at least 12 weeks. 7. Adequate organ function defined as: a.Absolute neutrophil count (ANC) ≥1.5×109/L without granulocyte colony-stimulating factor (G-CSF) support within 7 days preceding the laboratory assessment b.Platelet ≥100×109/L, without transfusion within 7 days preceding the laboratory assessment c.Hemoglobin ≥9 g/dL, without transfusion support within 7 days preceding the laboratory assessment d.Activated partial thromboplastin time/partial thromboplastin time (aPTT/PTT) ≤1.5×ULN e.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (if liver metastases are present, then ≤5×ULN is allowed) f.Total serum bilirubin ≤1.5×ULN, except for patients with known Gilbert's Syndrome in whom ≤3×ULN is permitted. Confirmation of Gilbert's diagnosis requires elevated unconjugated (indirect) bilirubin values; normal complete blood count in previous 12 months, blood smear, and reticulocyte count; normal aminotransferases and alkaline phosphatase in previous 12 months g.The patient is clinically euthyroid (whether treated or untreated) h.Renal: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min/1.73 m2 for patients with serum creatinine levels \>1.5×ULN i.Any Grade 3 or higher laboratory abnormalities should be discussed and approved by the Sponsor Medical Monitor or designee prior to enrollment (even if not considered clinically significant) 8. Fully recovered from acute toxic effects of prior anti-neoplastic therapies. The following minimum periods from treatment apply: 1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea). 2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor. 3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the Sponsor Medical Monitor or designee. d.Monoclonal antibodies: \>21 days must have elapsed from the infusion of last dose of antibody and toxicity related to antibody therapy must be recovered to Grade ≤1. e.Radiation therapy: Patients must have had their last fraction of craniospinal or focal irradiation a minimum of 8-12 weeks prior to enrollment. f.Stem cell transplant: Patients must be ≥3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study. g.For combination with pembrolizumab cohort: Patients with Grade ≤2 neuropathy may be eligible, as may patients with endocrine-related Grade ≤2 AEs requiring treatment or hormone replacement. 9. Active secondary malignancies will not be allowed, with the exception of: a.Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer b.Adequately treated Stage 1 cancer from which the patient is currently in remission and has been in remission for ≥2 years c.Low-risk prostate cancer with Gleason score \<7 and prostate-specific antigen \<10 ng/mL d.Any other cancer from which the patient has been disease-free for ≥3 years 10. Patient compliance and geographic proximity (as determined by the Investigator) to allow adequate follow-up. 11. Both male and female patients must be willing to consent to using highly effective contraception (refer to Section 9.1.10) prior to study entry, while on treatment, and at least 3 months thereafter. 12. Able to take oral medications. Exclusion Criteria: Patients will not be eligible for study participation if they meet ANY of the exclusion criteria. 1. Patients with melanoma only: i. Radiation therapy, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or not recovered from the AEs due to cancer therapies administered more than 4 weeks earlier ii.Expected to require any other form of systemic or localized antineoplastic t

FELLAShip to Better Health

NCT07220213
Recruiting
Conditions High Blood Glucose, High Cholesterol, Hi...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: FELLAship — TheFELLAship intervention, grounded in Social Cognitive Theory (SCT) and guided by the Socioecological Model (SEM), focuses on enhancing participants' skills, knowledge and beliefs, and self-efficacy to promote cardiovascular health (CVH). The program provides health education aligned with the Diabetes Prevention Program (DPP) and American Heart Association's Check. Change. Control. (AHA CCC) curriculum to support behavior change in diet, physical activity, tobacco use, sleep, and clinical care engagement. Team-based coaching and physical activity sessions strengthen behavioral confidence and skill application.

Primary Outcomes

  • Change From Baseline in Life's Essential 8 Overall Score (24 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: The Worship Center Christian Church
Contact Information
Study Contact:
LeAndrea D Anderson
2059960089
leandreaanderson@uabmc.edu
Jeff Givhan
205-451-1750
jgivhan@theworshipcentercc.org
The Worship Center Cristian Church
Interventions
  • Behavioral: FELLAship — TheFELLAship intervention, grounded in Social Cognitive Theory (SCT) and guided by the Socioecological Model (SEM), focuses on enhancing participants' skills, knowledge and beliefs, and self-efficacy to promote cardiovascular health (CVH). The program provides health education aligned with the Diabetes Prevention Program (DPP) and American Heart Association's Check. Change. Control. (AHA CCC) curriculum to support behavior change in diet, physical activity, tobacco use, sleep, and clinical care engagement. Team-based coaching and physical activity sessions strengthen behavioral confidence and skill application.
Study Locations (1 sites)
The Worship Center Cristian Church, Birmingham, Alabama 35210 United States
Eligibility Criteria
Inclusion Criteria: * Self-identified Black men * Age 18 or older * LE8 (Life's Essential 8) score (threshold not specified, but implies "less than ideal" CVH) * English speaking * Resides in the Metropolitan Birmingham, Alabama area * No physical activity restrictions imposed by a healthcare provider Exclusion Criteria: * Not identifying as Black and male * Under age 18 * Non-English speakers * Not living in the Birmingham, Alabama metro area * Having a healthcare provider-imposed restriction on physical activity * Ideal CVH (i.e., LE8 (Life's Essential 8) score above inclusion threshold)
Conditions Advanced HR+/HER2- Breast Cancer, Advanc...
Phase PHASE1, PHASE2
Enrollment 205
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GVV858 — Experimental
  • Drug: Fulvestrant — Approved medication
  • Drug: Letrozole — Approved medication

Primary Outcomes

  • Phase I: Incidence and severity of dose-limiting toxicities (DLTs) (28 days)
  • Phase I and phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Up to approximately 2 years)
  • Phase I and phase II: Frequency of dose interruptions, reductions and discontinuations (Up to approximately 2 years)
  • Phase I and phase II: Dose intensity (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-12-29
Completion: 2031-05-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 205 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
Kelsey Gates
kelsey.gates@emoryhealthcare.org
Emory University
Interventions
  • Drug: GVV858 — Experimental
  • Drug: Fulvestrant — Approved medication
  • Drug: Letrozole — Approved medication
Study Locations (15 sites)
Emory University, Atlanta, Georgia 30322 United States
Tennessee Oncology PLLC, Nashville, Tennessee 37203 United States
START, San Antonio, Texas 78229 United States
Novartis Investigative Site, Olomouc, 779 00 Czechia
Novartis Investigative Site, Odense C, 5000 Denmark
Novartis Investigative Site, Pierre-Bénite, 69495 France
Novartis Investigative Site, Jena, Thuringia 07740 Germany
Novartis Investigative Site, Essen, 45147 Germany
Novartis Investigative Site, Milan, MI 20141 Italy
Novartis Investigative Site, Milan, MI 20162 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Patients with one of the following histologically or cytologically confirmed advanced cancers: Phase I (patients with one of the following cancers, from whom no standard therapy is available or appropriate in the judgment of the investigator): * HR+/HER2- advanced breast cancer (aBC) with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional line of systemic therapy for metastatic disease. * Locally advanced or metastatic cancer with a CCNE1 amplification. For dose expansion only: no more than 3 prior lines of therapy for advanced or metastatic disease. * Metastatic castration-resistant prostate adenocarcinoma, with no documented neuroendocrine component, castrate level of testosterone, and no more than 3 prior lines of systemic therapy for metastatic disease. Phase II: * HR+/HER2- aBC with disease progression on or after an endocrine therapy in combination, with a CDK4/6 inhibitor for advanced disease with no more than 2 lines of endocrine therapy and no prior cytotoxic chemotherapy or antibody-drug-conjugate for advanced disease. \- Measurable disease as determined by RECIST v1.1. * BC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment. * metastatic Castration-Resistant Prostate Cancer (mCRPC) only: If no measurable disease is present per PCWG3 modified RECIST, then at least 1 metastatic lesion must be present on bone scan imaging. Exclusion Criteria: * Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values. * Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including myocardial infarction (MI), coronary artery bypass graft (CABG), long QT syndrome, or risk factors for Torsades de Pointes (TdP). * Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local therapy or increasing doses of corticosteroids within 2 weeks prior to study entry. * Patients with symptomatic visceral disease, including visceral crisis. * For patients with BC: Patient is concurrently using hormone replacement therapy. * Women of childbearing potential who are unwilling to use highly effective contraception methods, pregnant or nursing women. Other protocol-defined inclusion/exclusion criteria may apply.

Thai PainPREDICT Validation Study

NCT07195045
Recruiting
Conditions Painful Diabetic Neuropathy (PDN), Diabe...
Phase NA
Enrollment 277
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Painful diabetic neuropathy (PDN) is one of the most common and disabling complications of diabetes mellitus, substantially affecting quality of life, daily functioning, and health system burden. Early identification of PDN is crucial for timely treatment, prevention of complications such as foot ulcers and amputations, and for reducing healthcare costs. However, in Thailand there are limited culturally adapted and validated tools for screening PDN. PainPREDICT is an internationally validated questionnaire designed to characterize neuropathic pain profiles, but its adaptation for Thai patients has not yet been undertaken. In parallel, the use of mobile health technologies (mHealth) has the potential to expand access to screening and monitoring of chronic conditions, particularly in resource-limited settings.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Thai PainPREDICT Questionnaire and Mobile Application — The Thai PainPREDICT Questionnaire is a culturally adapted and validated version of an internationally recognized neuropathic pain assessment tool. In this study, it is administered via both paper form and a secure mobile application designed for Thai patients with diabetes. The app automates scoring, provides real-time feedback, and securely stores data in REDCap in compliance with Thai Personal Data Protection Act (PDPA). The intervention is used to screen for painful diabetic neuropathy and compare results against clinical diagnosis and neurophysiological testing, including DN4, nerve conduction studies, and quantitative sensory testing.

Primary Outcomes

  • Reliability and Validity of Thai PainPREDICT Questionnaire (Baseline through 12 months (Phases 1 and 2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-28
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 277 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chulalongkorn University
Principal Investigators:
  • Jakkrit Amornvit, MD (PRINCIPAL_INVESTIGATOR) - King Chulalongkorn Memorial Hospital
Contact Information
Study Contact:
Jakkrit Amornvit, MD
+66622169338
jakkrit.a@chula.ac.th
Tharadon Deepracha, MSc
+66622169338
tharadon.d@chulahospital.org
Jakkrit Amornvit, MD
+66622169338
jakkrit.a@chula.ac.th
King Chulalongkorn Memorial hospital, The Thai Red Cross Society
Interventions
  • Diagnostic Test: Thai PainPREDICT Questionnaire and Mobile Application — The Thai PainPREDICT Questionnaire is a culturally adapted and validated version of an internationally recognized neuropathic pain assessment tool. In this study, it is administered via both paper form and a secure mobile application designed for Thai patients with diabetes. The app automates scoring, provides real-time feedback, and securely stores data in REDCap in compliance with Thai Personal Data Protection Act (PDPA). The intervention is used to screen for painful diabetic neuropathy and compare results against clinical diagnosis and neurophysiological testing, including DN4, nerve conduction studies, and quantitative sensory testing.
Study Locations (1 sites)
King Chulalongkorn Memorial hospital, The Thai Red Cross Society, Pathum Wan, Bangkok 10330 Thailand
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older. * Diagnosed with type 1 diabetes mellitus or type 2 diabetes mellitus. * Able to communicate in Thai. * Willing and able to provide written informed consent. Exclusion Criteria: * Presence of neuropathy due to other causes (e.g., alcohol, chemotherapy, HIV, other systemic diseases). * Significant cognitive impairment or neurological conditions that prevent comprehension of the questionnaire. * Severe psychiatric illness that interferes with study participation.
Conditions Iron Deficiency Anemia of Pregnancy, Iro...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Validation of non-invasive measurement of zinc protoporphyrin for detection of iron deficiency in pregnancy. In addition, the impact of iron deficiency on the incidence of postpartum depression, restless legs syndrome, obstetric complications and quality of life will be examined.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: non-invasive measurement of zink protoporphyrin — validation of non-invasive measurement of zink protoporphyrin

Primary Outcomes

  • Accuracy of non-invasive zinc protoporphyrin for the detection of iron deficiency in pregnancy (through study completion, up to 3 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wuerzburg University Hospital
Contact Information
Study Contact:
Peter Kranke, MD, MBA
+4993120130050
kranke_p@ukw.de
Tobias Schlesinger, MD
+4993120130380
schlesinge_t@ukw.de
Peter Kranke, MD, MBA, MME
+49-931
kranke_p@ukw.de
University Hospital Würzburg
Interventions
  • Diagnostic Test: non-invasive measurement of zink protoporphyrin — validation of non-invasive measurement of zink protoporphyrin
Study Locations (1 sites)
University Hospital Würzburg, Würzburg, Bavaria 97080 Germany
Eligibility Criteria
Inclusion Criteria: * any timepoint during or up to 3 months after pregnancy * age ≥ 18 years * written informed consent Exclusion Criteria: * previous participation in this study * refusal of blood sampling * incapacity to give informed consent
Conditions Breast Cancer Patients
Phase NA
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Evaluation of the effectiveness and safety of laparoscopic assisted breast resection with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch for immediate one-step breast reconstruction and concurrent autologous fat transplantation in a prospective study

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation — Laparoscopic assisted mastectomy with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch, immediate one-step breast reconstruction and simultaneous autologous fat transplantation

Primary Outcomes

  • Incidence of serious complications after breast reconstruction surgery (One week after surgery, one month after surgery, three months after surgery, six months after surgery, and one year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-30
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • xiuchun chen (STUDY_DIRECTOR) - Henan Cancer Hospital
Contact Information
Study Contact:
xiuchun Chen
18603719919
cxc701024@163.com
minhao Lv
13838392355
zlyylvminhao2789@zzu.edu.cn
xiuchun Chen
18603719919
cxc701024@163.com
Henan Cancer Hospital
Interventions
  • Procedure: Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation — Laparoscopic assisted mastectomy with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch, immediate one-step breast reconstruction and simultaneous autologous fat transplantation
Study Locations (1 sites)
Henan Cancer Hospital, Zhengzhou, Henan 450000 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 to 70 years old; 2. In the first diagnosis of unilateral breast cancer patients, the maximum diameter of invasive tumor is ≤ 5cm, and there is no requirement for tumor size of carcinoma in situ in principle; 3. Patients undergoing preventive mastectomy are not allowed to be included in the study; 4. Clinical examination and auxiliary examinations suggest that the tumor is confined to the mammary gland and has not invaded the nipple areola complex, skin, or chest wall; 5. Clinical axillary lymph node negative (clinical physical examination and imaging suggest negative axillary lymph nodes; for suspected positive axillary lymph nodes, fine needle aspiration or hollow needle biopsy is required to confirm negative); 6. Sentinel lymph node biopsy negative; 7. Patients with low load positive axillary lymph nodes (isolated tumor cells, micro or macro metastases), but exempted from adjuvant radiotherapy after surgery; 8. Patients who are not suitable for breast conserving surgery or who are unwilling to undergo breast conserving surgery and plan to undergo laparoscopic assisted mastectomy with preservation of the nipple and areola, as well as immediate one-step breast reconstruction with a breast prosthesis combined with a chest muscle prosthesis and simultaneous fat transplantation; If frozen pathology or routine pathology indicates a positive posterior margin of the nipple, it is allowed to remove the nipple, but the areola must be preserved; 9. The volume of the prosthesis is less than 500cc; 10. During the observation period of the study, the affected side may consider re fat injection, but symmetrical surgery is not allowed on the healthy side; 11. ECOG score 0-1 points; 12. New adjuvant chemotherapy patients are allowed to be enrolled; 13. No smoking history or quitting smoking for at least 4 weeks; 14. The researcher determines that they are able to comply with the research protocol; 15. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers to not affect the study protocol can be enrolled normally; 16. After obtaining sufficient information, voluntarily participate and sign an informed consent form. Exclusion Criteria: 1. Specialized physical examination and/or auxiliary examination suggest that the tumor involves the nipple areola complex (including Paget's disease) or the skin; 2. Double breast cancer; 3. Bilateral breast reconstruction patients; 4. Patients who have undergone fat injection, breast augmentation with implants, and breast reduction surgery in the past; 5. Patients with incomplete immune function, poor control of diabetes and active smoking; 6. Patients with severe breast sagging; 7. Breast cup size ≥ E; 8. Accept two-step breast reconstruction using dilators/prostheses, autologous breast reconstruction, and breast reconstruction performed through open surgery; 9. Patients who have previously received and/or received postoperative radiotherapy for the reconstruction site or chest wall; 10. Patients who plan to undergo symmetrical surgery on the healthy breast during the visit period; 11. Patients with mental illnesses or abnormalities who are expected to be unable to independently complete the BREAST-Q scale; 12. Pregnant and lactating patients; 13. Poor compliance, unable to conduct relevant examinations and follow ups according to the trial requirements; 14. Suffering from serious accompanying diseases or other comorbidities that may interfere with planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.
Conditions HER2-positive Breast Cancer, Breast Canc...
Phase PHASE2
Enrollment 125
Locations 35 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Zanidatamab — Administered intravenously (IV)
  • Drug: Paclitaxel — Administered intravenously (IV)
  • Drug: Docetaxel — Administered intravenously (IV)
  • Drug: Carboplatin — Administered intravenously (IV)
  • Drug: Trastuzumab — Administered intravenously (IV)
  • Drug: Pertuzumab — Administered intravenously (IV)

Primary Outcomes

  • Number of participants with pCR (Up to 8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-24
Completion: 2030-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Ireland Limited
Contact Information
Study Contact:
Clinical Trial Disclosure & Transparency
215-832-3750
ClinicalTrialDisclosure@JazzPharma.com
Interventions
  • Drug: Zanidatamab — Administered intravenously (IV)
  • Drug: Paclitaxel — Administered intravenously (IV)
  • Drug: Docetaxel — Administered intravenously (IV)
  • Drug: Carboplatin — Administered intravenously (IV)
  • Drug: Trastuzumab — Administered intravenously (IV)
Study Locations (35 sites)
Oncology Institute, Long Beach, California 90805 United States
Cancer & Blood Research Center, Los Alamitos, California 90720 United States
Rocky Mountain Cancer Centers, Denver, Colorado 80218 United States
Holy Cross Hospital, Fort Lauderdale, Florida 33308 United States
The Oncology Institute, Lakeland, Florida 33812 United States
Accellacare of McFarland, Ames, Iowa 50010 United States
LSU Health Sciences Center, Shreveport, Louisiana 71103 United States
New England Cancer Specialists, Scarborough, Maine 04074 United States
Maryland Oncology Hematology, Laurel, Maryland 20707 United States
Henry Ford Hospital, Detroit, Michigan 48202 United States
Eligibility Criteria
Inclusion Criteria: 1. Has newly diagnosed Stage II or III histologically confirmed invasive breast carcinoma. 2. Has histologically confirmed HER2-positive breast cancer 3. Has a known hormone receptor (HR) status of the primary tumor 4. Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive. 5. Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy. 6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate organ function 8. Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 6 weeks prior to randomization. 9. Adequate contraceptive precautions 10. Participants with known HIV are eligible unless: 1. CD4+ T Cell count is less than or equal to 350 microliters (uL) 2. Detectable viral load, or 3. Receiving protease inhibitors or cobicistat Exclusion Criteria: 1. Has Stage IV (metastatic) breast cancer. 2. Has bilateral breast cancer. 3. Has a history of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect the participant's involvement in the study. 4. Has uncontrolled hypertension 5. Has significant symptoms from peripheral neuropathy 6. Has an active uncontrolled infection 7. Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab or other study interventions. 8. Known active hepatitis B or C infection. 9. Has another malignancy diagnosed within the last 5 years. Exceptions include previously treated non melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ. Participants with prior ipsilateral ductal carcinoma in situ (DCIS) or invasive breast cancer are not eligible. 10. Was treated with surgery, chemotherapy, anti-HER2 therapy, radiation therapy, endocrine therapy, or experimental therapy for invasive breast cancer 11. Is planning to receive concurrent therapy with any other investigational agent or anti-cancer therapy not specified in the protocol 12. Receipt of a live vaccine within 4 weeks prior to enrollment 13. Has a known hypersensitivity to any components of the study interventions, including chemotherapy
Conditions Loneliness, Social Isolation, Depression...
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Older adults in Canada are experiencing increasing levels of social isolation, loneliness, and mental health challenges, including anxiety and depression - trends that have worsened during and following the COVID-19 pandemic. Research consistently shows that loneliness and social isolation are associated with poorer mental and physical health outcomes, increased risk of dementia, and increased mortality. At the same time, social connection has a strong protective impact on health and well-being. Community-based programs that promote both social engagement and psychological support are urgently needed, particularly since older adults are less likely to access formal mental health services. Approximately 3-11% of older adults meet diagnostic criteria for mood or anxiety disorders each year, with even more experiencing elevated symptoms that greatly influence quality of life. Subsyndromal depression in late life is estimated to occur two to three times more often than major depressive disorder. Despite these needs, up to 70% of older adults with anxiety or mood disorders do not access psychological services, often due to low mental health literacy or practical barriers to care. At the same time, participation in community activities is associated with improved emotional well-being, greater social support, and lower rates of depression and anxiety. To bridge this need for support, our team developed and pilot-tested The CONNECT Program - a group-based mental health intervention for adults 55 years and older, delivered via telephone or virtually. The CONNECT Program is grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and theories of successful aging, and aims to improve psychological flexibility; reduce loneliness, social isolation, and co-occurring symptoms of depression and anxiety. A Manitoba pilot study (N = 34) demonstrated promising outcomes in terms of feasibility, acceptability, and preliminary effectiveness with the telephone-based group intervention. The current trial will evaluate the implementation and effectiveness of The CONNECT Program in four Canadian provinces (British Columbia, Manitoba, New Brunswick, Saskatchewan), using an implementation-effectiveness hybrid design and a crossover randomized controlled trial. This study compares The CONNECT Program, delivered via telephone or virtually, to routine community programming (i.e., community participation as usual), which may occur in telephone, virtual, or in-person formats. The primary outcome is psychological flexibility; secondary outcomes include loneliness, social isolation, anxiety, depression, emotional support, mental health literacy. Implementation outcomes will be evaluated following the Proctor et al. framework. This trial will contribute evidence on the mental health needs of adults 55+ and the value of low-barrier, community-based programs delivered remotely. Findings will guide further national and international implementation of The CONNECT…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: The CONNECT Program — A group-based telehealth intervention grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and successful aging theories, aimed at reducing social isolation, loneliness, and mental health symptoms among adults 55+. Delivered over six weeks via group phone or Zoom sessions. The CONNECT Program includes 6 weekly 90-minute group sessions, with structured workbooks and homework. The CONNECT Program is delivered in two modalities (group telephone or Zoom videoconferencing).
  • Behavioral: Community Participation as Usual (Service as Usual) — These community-based programs may include social, educational, or recreational group sessions that are already offered by local organizations - either in person, by phone, or virtually.

Primary Outcomes

  • Change in Psychological Flexibility from Baseline (Acceptance and Action Questionnaire-II) (At baseline (Week 0), after community-based programming as usual if delivered first (Week 6), after the CONNECT program (Week 6 or 12 depending on sequence), and at 6-month follow-up (Week 30-36).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-08
Completion: 2026-12-31
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Manitoba
Collaborators: A & O: Support Services for Older Adults, Brella Community Services Society, Senior Citizens Assistance Program, CHI - Centre for Healthcare Innovation
Contact Information
Study Contact:
Kristin AA Reynolds, PhD
204-474-8260
Kristin.Reynolds@umanitoba.ca
Kristin Reynolds
204-474-8260
Kristin.Reynolds@umanitoba.ca
University of Manitoba
Interventions
  • Behavioral: The CONNECT Program — A group-based telehealth intervention grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and successful aging theories, aimed at reducing social isolation, loneliness, and mental health symptoms among adults 55+. Delivered over six weeks via group phone or Zoom sessions. The CONNECT Program includes 6 weekly 90-minute group sessions, with structured workbooks and homework. The CONNECT Program is delivered in two modalities (group telephone or Zoom videoconferencing).
  • Behavioral: Community Participation as Usual (Service as Usual) — These community-based programs may include social, educational, or recreational group sessions that are already offered by local organizations - either in person, by phone, or virtually.
Study Locations (1 sites)
University of Manitoba, Winnipeg, Manitoba R3T 2M8 Canada
Eligibility Criteria
Inclusion Criteria: * Adults aged 55 years or older * Able to speak, read, and understand English * Can manage hearing or vision changes well enough to participate in group conversations * Self-reported experiences of loneliness, social isolation, and/or mental health challenges (e.g., anxiety or depressive symptoms) Exclusion Criteria: * Cannot communicate in English (verbal or written)
Conditions Depression, Anxiety
Phase EARLY_PHASE1
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference. Whether the positive effects last over time, and if getting access to these foods later (instead of right away) still helps people feel better, will also be assessed.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Other: Traditional Country Foods — Participants will receive weekly distributions of traditional foods, including caribou and fish. Guided conversations will explore changes in dietary habits, emotional well-being, and cultural connections
  • Behavioral: Cultural Workshops — Weekly workshops led by Elders will focus on traditional country food, food preparation, and sharing practices, enhancing cultural identity and community bonds. Participants will also engage in cultural camps where they will be led by Elders in land based teachings on country food.

Primary Outcomes

  • Cultural Acceptability of the Intervention- Qualitative Interviews (From enrolment to the end of treatment at 12 weeks)
  • Cultural Acceptability of the Intervention- Participant Diaries (From enrolment to the end of treatment at 12 weeks)
  • Participant satisfaction and perceived impact on mental health (From enrolment to the end of treatment at weeks 4, 8, and 12.)
  • Mental Health Impacts (Baseline (enrolment))
  • Mental Health Impacts - 4 weeks (4 weeks after enrolment)
  • Mental Health Impacts (8 weeks after enrolment)
  • Mental Health Impacts (12 weeks after enrolment)
  • Participant Satisfaction- Participant Diaries (Baseline (at enrolment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-10-15
Completion: 2026-09-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Collaborators: Aqqiumavvik - Arviat Wellness Society
Principal Investigators:
  • Wayne Clark, Ed.D (PRINCIPAL_INVESTIGATOR) - University of Alberta
  • Justin Ezekowitz, MD (PRINCIPAL_INVESTIGATOR) - University of Alberta
Contact Information
Study Contact:
Wayne Clark, Ed.D
7804928482
wclark1@ualberta.ca
Tibetha Kemble, PhD
5875902693
kemble@ualberta.ca
Shirley Tagalik, MEd
2042180866
inukpaujaq@gmail.com
Aqqiumavvik Society
Interventions
  • Other: Traditional Country Foods — Participants will receive weekly distributions of traditional foods, including caribou and fish. Guided conversations will explore changes in dietary habits, emotional well-being, and cultural connections
  • Behavioral: Cultural Workshops — Weekly workshops led by Elders will focus on traditional country food, food preparation, and sharing practices, enhancing cultural identity and community bonds. Participants will also engage in cultural camps where they will be led by Elders in land based teachings on country food.
Study Locations (2 sites)
Aqqiumavvik Society, Arviat, Nunavut X0C 0E0 Canada
Aqqiumavvik - Arviat Wellness Society, Arviat, Nunavut X0C0E0 Canada
Eligibility Criteria
Inclusion Criteria: * Inuit * Able to consent to study participation * Participating in community wellness programs facilitated by the Aqqiumavvik Wellness Centre within 6 months prior to screening * Willing to consume country foods provided as part of the intervention * Willing to engage in individual and group activities, including guided conversations and cultural workshops * 18-65 years of age Exclusion Criteria: * Less than 18 years of age * Greater than 65 years of age * Unable to consent to study participation * Mental health conditions requiring immediate clinical intervention * Known allergies or medical conditions that prevent the consumption of traditional country foods * Physical or logistical barriers that prevent participation in weekly activities